生物制药特许权使用费公司 Royalty Pharma 获得一致“买入”评级，TD Cowen 等分析师上调了其前景。 Royalty Pharma, a biopharmaceutical royalties firm, receives a consensus "Buy" rating with analysts like TD Cowen boosting its outlook.

皇家药店(RPRX)是一家购买生物药品使用费和为工业创新提供资金的公司,它得到混合分析师的评分,但获得共识的“Buy”,目标价格为41.67美元。 Royalty Pharma (RPRX), a company that buys biopharmaceutical royalties and funds industry innovations, has seen mixed analyst ratings but a consensus "Buy" with a target price of $41.67. 股价经历了波动的贸易量, 最近, TD Cowen将股票升级为“强购 ” 。 The stock has experienced fluctuating trading volumes, and recently, TD Cowen upgraded it to a "strong-buy." 皇家药房还每年支付0.84美元的红利,收益率为3.33%。 Royalty Pharma also pays an annual dividend of $0.84, yielding 3.33%.